Is Sarepta Therapeutics worth $10 billion? Can you incarcerate a unicorn? And how many jobs can one man reasonably hold?

We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation about the implications of Sarepta’s big week on Wall Street followed by an examination of the legal predicament (and romantic entanglements) of Theranos. Andreessen Horowitz venture capitalist Vijay Pande joins us to discuss how discerning biotech investors approach artificial intelligence, and then we talk about Atul Gawande’s work-life balance, the risks of biotech exuberance, and how to get rich on “right to try.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy